Accenture has taken a 6 percent stake in Carlsbad, Calif.-based BioQ, maker of a software that searches for regulatory approval data. The equity partnership is designed to improve the quality and timeliness of electronic regulatory data submissions for the pharmaceutical, biotech and medical device industries. Our deal with Accenture is an alliance where we're working together to service the medical industry helping them with the timeliness of information, document management and federal compliance. The alliance combines Accenture's industry experience and technology skills with BioQ's expertise in creating interactive intelligent agent-based knowledge management, distance learning and collaboration tools. As part of the agreement, Accenture will receive an equity stake in BioQ. Accenture reinvention Accenture and BioQ will jointly develop and market software that supports regulatory intelligence with a focus on improving regulatory compliance in the development of new medical products.
Likely clients are drug discovery biotechnology firms and medical device makers.
The collaboration with BioQ gives Accenture access to more biotechnology companies and arms existing pharmaceutical clients with a needed information resource. BioQ's intelligence system, which gathers and delivers information based on user profiles and user activities, will be launched this summer. In the future, BioQ will add distance learning and collaboration tools to support regulatory compliance and electronic submissions activities. Accenture works with roughly 90 percent of the top pharmaceutical corporations. E-mail her with story ideas or comments.